Recurrent Gastrointestinal Carcinoid Tumor Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028801 (Recurrent Gastrointestinal Carcinoid Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment